JP2009527484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527484A5 JP2009527484A5 JP2008555417A JP2008555417A JP2009527484A5 JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5 JP 2008555417 A JP2008555417 A JP 2008555417A JP 2008555417 A JP2008555417 A JP 2008555417A JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- zileuton
- composition according
- single crystal
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005332 zileuton Drugs 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 14
- 208000028867 ischemia Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010069351 acute lung injury Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102000003820 Lipoxygenases Human genes 0.000 claims description 2
- 108090000128 Lipoxygenases Proteins 0.000 claims description 2
- 208000000592 Nasal Polyps Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010000228 Abortion infected Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000002359 Septic Abortion Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77557906P | 2006-02-21 | 2006-02-21 | |
| PCT/US2007/004488 WO2007098189A2 (en) | 2006-02-21 | 2007-02-21 | New crystal forms and pharmaceutical compositions of (+) -r-zileuton |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009527484A JP2009527484A (ja) | 2009-07-30 |
| JP2009527484A5 true JP2009527484A5 (cg-RX-API-DMAC7.html) | 2010-04-08 |
Family
ID=38437967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555417A Pending JP2009527484A (ja) | 2006-02-21 | 2007-02-21 | （＋）−ｒ−ジロートンの新規結晶形態および医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8003684B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2409973A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009527484A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007217770B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2642216A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007098189A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| CN101674823A (zh) * | 2007-01-05 | 2010-03-17 | 基础治疗公司 | 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病（例如哮喘）的r-齐留通 |
| CN101808642B (zh) * | 2007-09-28 | 2012-05-02 | 布里格海姆妇女医院公司 | 肥大细胞稳定剂治疗肥胖症 |
| CN102413825A (zh) | 2009-04-29 | 2012-04-11 | 阿马里纳股份公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| CA2844775A1 (en) * | 2011-08-23 | 2013-02-28 | Cornerstone Therapeutics Inc. | Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
| KR101462474B1 (ko) * | 2013-10-30 | 2014-11-19 | 주식회사 큐리언트 | 질레우톤 크림 제형의 국소용 항염증 약학적 조성물 |
| US9855243B2 (en) | 2013-10-30 | 2018-01-02 | Qurient Co., Ltd. | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation |
| JP2017518325A (ja) * | 2014-06-20 | 2017-07-06 | アビラジェン セラピューティクス インコーポレイテッドＡｖｉｒａｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ６−｛２−［１−（６−メチル−３−ピリダジニル）−４−ピペリジニル］エトキシ｝−３−エトキシ−１，２−ベンゾイソオキサゾールの無水結晶性遊離塩基形態 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US279263A (en) * | 1883-06-12 | Eobeet t | ||
| EP0279263B1 (en) * | 1987-02-10 | 1993-08-04 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| EP0697868A4 (en) * | 1993-05-10 | 1998-04-08 | Sepracor Inc | METHOD AND COMPOSITION USING OPTICALLY PURE (+) - ZILEUTON |
| EP0708753A4 (en) | 1993-07-14 | 1996-10-02 | Smithkline Beecham Corp | SYNTHESIS OF ACID ADDITION SALTS OF HYDROXYLAMINES |
-
2007
- 2007-02-21 WO PCT/US2007/004488 patent/WO2007098189A2/en not_active Ceased
- 2007-02-21 EP EP11176982A patent/EP2409973A1/en not_active Withdrawn
- 2007-02-21 JP JP2008555417A patent/JP2009527484A/ja active Pending
- 2007-02-21 AU AU2007217770A patent/AU2007217770B2/en not_active Ceased
- 2007-02-21 EP EP07751259A patent/EP2001861A2/en not_active Ceased
- 2007-02-21 US US11/709,299 patent/US8003684B2/en not_active Expired - Fee Related
- 2007-02-21 CA CA002642216A patent/CA2642216A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009527484A5 (cg-RX-API-DMAC7.html) | ||
| US20250163023A1 (en) | Synthesis of omecamtiv mecarbil | |
| US10035802B2 (en) | Solid state forms of ibrutinib | |
| JP2013529647A5 (cg-RX-API-DMAC7.html) | ||
| JP2014515372A5 (cg-RX-API-DMAC7.html) | ||
| JP2019505568A5 (cg-RX-API-DMAC7.html) | ||
| WO2014152270A1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| CN106316889B (zh) | 依度沙班中间体的制备方法 | |
| HUE031416T2 (en) | Preparation of 2- (5-Bromo-4- (4-cyclopropylnaphthalen-1-hydrazine) -4H-1,2,4-triazole-3-hydrazine) acetic acid \ t | |
| CN108947891B (zh) | 利用三光气安全制备匹莫范色林及其酒石酸盐的方法 | |
| JP2007514746A5 (cg-RX-API-DMAC7.html) | ||
| JP2011513485A5 (cg-RX-API-DMAC7.html) | ||
| JP6556293B2 (ja) | 純粋なニロチニブ及びその塩の調製のための方法 | |
| US10519117B2 (en) | Crystal forms of 6-bromo-3-hydroxy-2-pyrazinecarboxamide | |
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| CN102321073A (zh) | 一种尼罗替尼的制备方法 | |
| JP2013541589A5 (cg-RX-API-DMAC7.html) | ||
| CN103951601B (zh) | 2-乙酰基-1-吡咯啉的合成方法 | |
| ES2710312T3 (es) | Un procedimiento para la preparación de montelukast sódico | |
| CN105777617A (zh) | 色瑞替尼的合成中间体及其制备方法 | |
| JP6387349B2 (ja) | 逆転写酵素阻害剤の結晶形態 | |
| JP4530287B2 (ja) | オキサセフェムの結晶 | |
| WO2012153225A1 (en) | Improved processes for obtaining high purity of dronedarone hydrochloride | |
| CN101896496B (zh) | 4-脱氧-4-氟-d-葡萄糖衍生物的制造方法 | |
| EP3374349A1 (en) | Process for the preparation of eltrombopag olamine |